Datasets

Uterine Carcinosarcoma (Johns Hopkins, Nat Commun 2014)

cBioPortal study layout (data_clinical_patient/sample, data_mutations, meta_study) describing 22 female patients with uterine carcinosarcoma (ONCOTREE UCS) sequenced at Johns Hopkins on GRCh37. Charts are grouped into analysis-stage tabs based on available data.

TCGA Uterine Carcinosarcoma

cBioPortal study bundle with TCGA barcodes from the N5/N6 tissue source sites and an all-female cohort of 57 patients with post-menopausal status — characteristic of TCGA Uterine Carcinosarcoma (UCS). Charts are grouped into analysis-stage tabs based on available data.

Ovarian Serous Cystadenocarcinoma (TCGA, PanCancer Atlas)

TCGA ovarian serous cystadenocarcinoma study: clinical samples are all OV/Serous Ovarian Cancer (ONCOTREE SOC) with TCGA-04-* identifiers and the full PanCancer Atlas accessory tables (arm-level CNA, methylation HM27/HM450 merged, RPPA, phosphoprotein, MSI sc…. Charts are grouped into analysis-stage tabs based on available data.

MSK-IMPACT Endometrial Cancer

MSK-IMPACT Endometrial Cancer cohort of 33 female patients with Endometrial Cancer profiled by MSK-IMPACT panels (IMPACT410/468), with MSI scores, TMB, OS, and matched somatic calls.

MSK SPECTRUM - High-Grade Serous Ovarian Cancer Multimodal Atlas

The MSK SPECTRUM (SPatiotemporal Evolution of Cancer Traced Using Multimodalities) project is a comprehensive, interdisciplinary study focused on understanding the development, spread, and treatment resistance of High-Grade Serous Ovarian Cancer (HGSOC).

Cellular heterogeneity of human fallopian tubes in normal and hydrosalpinx disease states

Cellular heterogeneity of human fallopian tubes in normal and hydrosalpinx disease states (Ulrich et al., 2022) presents a single-cell RNA-seq atlas of the human fallopian tube (FT) in both healthy and diseased states.

Australian National Gynae-Oncology Registry (NGOR)

The National Gynae-Oncology Registry (NGOR) is a clinical quality registry that monitors the quality of care provided to patients diagnosed with gynaecological cancers (cancers of the female reproductive system) in Australia. The registry is managed by a team in the Cancer Research Program, part of the School of Public Health and Preventive Medicine at Monash University.

A single-cell atlas of the aging mouse ovary (Isola et al. 2024, Nature Aging)

A 2024 study titled "A single-cell atlas of the aging mouse ovary," frequently discussed in relevant literature, provides a comprehensive map of transcriptomic changes in ovaries from young (3-month) and reproductively aged (9-month) mice. The atlas reveals a doubling of immune cells (particularly lymphocytes) and enhanced fibrotic pathways in aged mice.

MSK Endometrial Cancer Ancestry Cohort

The MSK Endometrial Cancer Ancestry Cohort (msk_ec_anc) study, published in Cancer Discovery in 2023, is a comprehensive genomic analysis of 1,882 endometrial cancer patients aimed at understanding the molecular basis of racial disparities in endometrial cancer survival.

Mismatch Repair Deficient Endometrial Cancer

Research from Memorial Sloan Kettering (MSK) between 2022 and 2023 reveals that mismatch repair deficient (MMRd) endometrial cancer is heterogeneous, with prognosis and immunotherapy response driven by whether the deficiency is caused by genetic mutations (better prognosis) or epigenetic silencing (worse prognosis). The findings suggest that distinguishing between these subtypes can improve treatment strategies, such as using PD-1 inhibitors for mutational types and exploring organ preservation for early-stage cases.

Metastatic Endometrial Cancer - HER2/ERBB2 cohort

This study analyzes 69 metastatic endometrial cancer samples, identifying ERBB2 (HER2) pathogenic mutations as defining a distinct, often non-amplified subgroup (84% of cases) characterized by low HER2 expression (0/1+ in 66% of cases) and high co-occurrence with MSI-High/POLE subtypes. Findings suggest that while ERBB2-mutated cases frequently present with low HER2 expression, they represent a actionable subgroup for HER2-targeted antibody-drug conjugates and immunotherapies.

Low-Grade Serous Ovarian Cancer - MAPK pathway

Low-Grade Serous Ovarian Cancer (MSK, 2022) - MAPK pathway. cBioPortal study with cancer_study_identifier 'lgsoc_mapk_msk_2022', containing 119 low-grade serous ovarian cancer (LGSOC) samples profiled at MSK with targeted sequencing focused on MAPK pathway alterations. Charts are grouped into analysis-stage tabs based on available data.

Human Ovary Single-Cell Atlas

The Human Ovary Single-Cell Atlas (Jones et al., 2024), published in Science Advances, maps the cellular, functional, and spatial organization of the reproductive-age human ovary using scRNA-seq and spatial transcriptomics. This dataset facilitates research on follicle development and ovarian aging by providing high-resolution data on oocytes, granulosa, and theca cells.

CPTAC Uterine Corpus Endometrial Carcinoma - Discovery Study

The CPTAC Uterine Corpus Endometrial Carcinoma (UCEC) Discovery Study is a comprehensive proteogenomic project by the National Cancer Institute (NCI) that analyzed 138 tumors and 20 normal tissues. It provides deep multi-omics data (proteome, acetylome, RNA-seq) to identify druggable pathways, molecular subtypes, and novel biomarkers for improved endometrial cancer diagnosis and treatment.

Circulating Tumor DNA in Endometrial Cancer

Circulating tumor DNA (ctDNA) acts as a highly sensitive, non-invasive biomarker for detecting minimal residual disease and monitoring recurrence in endometrial cancer (EC). Research shows ctDNA positivity correlates with poor prognosis and higher recurrence rates. It often detects recurrence earlier than imaging, offering a tool to guide treatment.

Chinese Cancer Genome Consortium (CCGC)

Publicly-funded network of 30+ university hospitals and research institutions. Coordinates large-scale cancer genome studies using next-generation sequencing. Shares common research platform for cancer genomics.

IQVIA Oncology EMR (Europe/Global)

Multi-country oncology EMR database extracted from European cancer hospitals. Part of IQVIA's Oncology Evidence Network. EMR data directly from clinical records with structured/unstructured notes. Linkable to other IQVIA real-world data assets. OMOP-standardized data.

AOCR Biobank (Netherlands)

Dutch nationwide, multicenter biobank. Prospective collection with 1,093 patients, 1,339 tissue samples, 2,280 blood samples. Advanced/metastatic ovarian, fallopian tube, primary peritoneal cancers. 73.4% HGSOC.

Ovarian Cancer Organoid Biobank (UMC Utrecht)

Dutch biobank of patient-derived organoids representing spectrum of ovarian neoplasms. 56 organoid lines from 32 patients. WGS data for organoids, matched tumors, and blood. Organoids recapitulate histological/genomic features.

AOCS — Australian Ovarian Cancer Study

National collaborative research program and biobank, one of largest ovarian cancer studies globally. >3,000 women with invasive or borderline ovarian cancer plus 1,066 controls. Comprehensive biospecimen collection with extensive clinical and epidemiological data.

C-CAT Database (Japan)

National clinico-genomic database containing comprehensive genomic profiling test results from >3,000 gynecological malignancies. Real-world patients with poor prognoses who completed standard treatments.

GEICO-RNBB Virtual Clinical Registry (Spain)

Multicentre virtual clinical registry developed by GEICO (Spanish Group of Ovarian Cancer Research) and Spanish Biobank Network (RNBB). Prospective collection of real-world data and biospecimens from gynecological cancer patients across 30+ active sites in Spain.

Bassiouni et al. 2026 — Ovarian Cancer Single-Cell WGS + Spatial Transcriptomics

City of Hope / USC dataset with matched single-cell WGS (scWGS) and spatial transcriptomics from 5 late-stage treatment-naïve primary ovarian carcinomas (HGSOC and clear cell). Characterizes intratumoral heterogeneity at single-cell genomic resolution with spatial gene expression.

AnVIL — NHGRI Analysis, Visualization, and Informatics Lab-Space

NHGRI cloud-based genomics platform (Terra/Google Cloud) providing controlled-access to large-scale genomic datasets (TCGA, GTEx, TOPMed) in a compute-accessible environment. Analyze data in the cloud without local data transfers using Jupyter, WDL workflows, or R/Bioconductor.

NCI PDMR — Patient-Derived Models Repository

NCI repository providing access to patient-derived cancer models (PDX, organoids, cell lines) with associated genomic characterization. Gynecologic cancer models included. Links each model to donor clinical metadata, somatic mutations, CNV, and RNA-seq where available.

FinnGen

Finnish public–private partnership with genome + health data from ~500,000 Finnish biobank participants with national health registry linkage. Gynecologic cancer GWAS results and PheWAS data available as open-access summary statistics via FinnGen browser.

OCAC — Ovarian Cancer Association Consortium GWAS

Largest international consortium for ovarian cancer genetic epidemiology. GWAS using iCOGS (~200K SNPs) and OncoArray (~500K SNPs) platforms, identifying dozens of OV susceptibility loci. Data deposited in dbGaP and EGA.

Project Data Sphere — Oncology Trial Data

Independent not-for-profit initiative providing access to de-identified patient-level data from oncology clinical trials, including gynecologic cancer studies. Emphasizes data democratization for re-analysis of completed trials.

AACR Project GENIE

International pan-cancer genomic data sharing consortium aggregating real-world clinical-grade NGS data from major cancer centers. Targeted panel sequencing with associated clinical outcomes. All major gynecologic cancer types represented.

Regner et al. 2021 — Gynecologic scRNA-seq/scATAC-seq (GSE173682)

Matched scRNA-seq and scATAC-seq profiles from freshly resected human ovarian and endometrial tumors. One of the first paired chromatin-accessibility + transcriptome datasets at single-cell resolution for these cancer types. Enables study of regulatory elements, TF activity, and intratumoral heterogeneity.